sorafenib + tipifarnib

The combination of sorafenib and tipifarnib is a targeted therapy approach that has been studied in clinical trials, particularly for advanced cancers including thyroid cancer. This combination targets multiple kinase pathways simultaneously, with sorafenib inhibiting Raf-1, RET, KIT, PDGFR, and VEGFR2, while tipifarnib inhibits farnesyltransferase to prevent Ras activation[1][2]. ## Mechanism of Action Sorafenib is a multikinase inhibitor that targets several proteins involved in tumor growth and angiogenesis, including Raf-1, RET, KIT, platelet-derived growth factor receptor (PDGFR), and vascular endothelial growth factor receptor 2 (VEGFR2)[1][2]. Tipifarnib is a farnesyltransferase inhibitor that prevents the activation of Ras proteins, which are important in cell signaling pathways leading to cell proliferation[1][2]. The rationale behind combining these agents is that they target different but interconnected parts of the Ras/Raf/MEK/ERK pathway, potentially providing synergistic or additive effects in cancer treatment[2][3]. This combination specifically targets the RET/Ras/Raf/IKKB/NF-κB pathway, which is particularly relevant in thyroid cancers[3]. ## Clinical Development A phase I trial evaluated this combination using a standard 3+3 dose-escalation design with a 28-day cycle (sorafenib daily and tipifarnib for 21 days, orally)[1][2]. The maximum tolerated dose (MTD) was determined to be sorafenib 400mg in the morning/200mg in the evening and tipifarnib 100mg twice daily[1][3]. At higher doses, the dose-limiting toxicity was rash[1][3]. The combination showed particular efficacy in patients with medullary thyroid cancer (MTC), especially those with RET gene mutations[1][6]. In the clinical trials: - 50% of MTC patients achieved partial responses and 50% had stable disease[6] - 87% of differentiated thyroid cancer (DTC) patients and 90% of MTC patients had durable responses (PR or SD ≥6 months)[6] - Median progression-free survival was 20 months in DTC and 15 months in MTC[6] - At 24 months, overall survival was 79% in DTC and 88% in MTC[6] Common side effects included rash, hyperglycemia, diarrhea, and hand-foot skin reaction[1][6]. The combination was generally well-tolerated, though at lower doses of each drug than when used as single agents[2]. Pharmacokinetic analysis showed that while sorafenib maintained a similar profile to when used alone, tipifarnib plasma concentrations were lower than expected, suggesting possible drug interactions[3]. Despite the low doses of tipifarnib, about 25% of patients had significant reduction in farnesyltransferase levels[1]. This combination represents an important contribution to the field of targeted therapy combinations and has shown promising results, particularly in thyroid malignancies with specific genetic mutations.